5 Stocks To Buy Now According To This Elite Hedge Fund

#3 Blackstone Group LP (NYSE:BX)

Shares held (as of September 30): 467,129
Total Value (as of September 30): $14.79 million
Percent of Portfolio (as of September 30): 5.03%

Although the era of cheap debt may be coming to an end as the Federal Reserve prepares to hike interest rates, private equity titan Blackstone Group LP (NYSE:BX) is doing just fine. Analysts are optimistic on the company, with 14 analysts assigning the giant a ‘Buy’ rating, and just one analyst giving Blackstone Group a ‘Hold’ rating. The analysts at Argus have a ‘Buy’ rating with a $43 price target on the stock, while analysts at RBC Capital have an ‘Outperform’ rating and a $44 price target. Overall, analysts have a consensus price target of $44.07 per share, giving shares an upside of 29.11% from current levels. Shares are up by 8.79% year-to-date.

#2 Oracle Corporation (NYSE:ORCL)

Shares held (as of September 30): 432,951
Total Value (as of September 30): $15.64 million
Percent of Portfolio (as of September 30): 5.32%

Although NoSQL and open source competitors may be viable alternatives for startups, Oracle Corporation (NYSE:ORCL)’s databases are still the gold standard for large corporations and governments around the world. Since databases are at the heart of almost every corporation, Oracle’s cash flows have great visibility. The long term relationship it has with many of Fortune 500 companies allows Oracle to sell other software and services at relatively low marketing costs. At a forward P/E of 13.87, Oracle is also cheap, particularly when contrasted with the NASDAQ index’s forward P/E of 19.85. Boykin Curry’s Eagle Capital Management owned 42.24 million shares of Oracle at the end of June.

#1 Zimmer Biomet Holdings Inc (NYSE:ZBH)

Shares held (as of September 30): 200,598
Total Value (as of September 30): $18.84 million
Percent of Portfolio (as of September 30): 6.41%

Zimmer Biomet Holdings Inc (NYSE:ZBH) is Welch Capital Partners’s number one position, good for 6.41% of the fund’s equity portfolio. Zimmer Biomet Holdings Inc (NYSE:ZBH) recently reported solid third quarter earnings results, with an EPS of $1.64 on revenues of $1.76 billion, up 58.6% year-over-year. Management is restarting the company’s share repurchase program, which was temporarily suspended in April of last year due to the Biomet transaction. There is currently $599.5 million left in the share repurchase authorization. Shares trade at a reasonable forward P/E of 13.67 and analysts have a consensus price target of $127.71 on the stock, suggesting shares have 19.4% upside potential.

Disclosure: None